View Cart  

Jazz Appears to Win on Patent Claim Terms in Xyrem Fight

A district court judge has largely sided with Jazz Pharmaceuticals’ definitions for patents on its narcolepsy drug Xyrem, and the outcome looks like a “clear win” in Jazz’s legal struggle to prevent generic competition from Roxane Laboratories, one analyst says.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00